While compounded medications do not go through the same FDA pre-market approval process as commercially manufactured drugs, they must meet strict safety and quality standards and be prescribed by a licensed healthcare provider
A few things to keep straight: these peptides are not FDA-approved drugs for human use
Here's why the pre-mixed blend has a catch: if all three are in one vial at fixed ratios, you can't adjust one without adjusting all of them
The outcome could have implications for how these treatments are accessed and monitored going forward, with speculation pointing toward loosening existing restrictions that were set in place in 2023
There are no routine provider check-ins, no required follow-up visits, and no dose-adjustment cadence laid out for patients after approval
Taken together, the GLP-1 experience illustrates both the promise and the limits of peptide pharmacology